Valuation: biote Corp.

Market Cap 33.55M 29.96M 27.95M 25.39M 47.78M 3.25B 48.25M 336M 131M 1.65B 126M 123M 5.31B P/E 2026 *
-5.71x
P/E 2027 * 6.88x
Enterprise Value 33.55M 29.96M 27.95M 25.39M 47.78M 3.25B 48.25M 336M 131M 1.65B 126M 123M 5.31B EV / Sales 2026 *
0.19x
EV / Sales 2027 * 0.18x
Free-Float
77.11%
Yield 2026 *
-
Yield 2027 * -
1 day+5.41%
1 week+0.86%
Current month-3.31%
1 month-22.52%
3 months-48.23%
6 months-20.41%
Current year-55.00%
1 week 1.06
Extreme 1.06
1.25
1 month 1.06
Extreme 1.06
1.46
Current year 1.06
Extreme 1.06
2.68
1 year 1.06
Extreme 1.06
3.26
3 years 1.06
Extreme 1.06
8.44
5 years 1.06
Extreme 1.06
10.52
10 years 1.06
Extreme 1.06
10.52
Manager TitleAgeSince
Chief Executive Officer 49 2026-06-11
Chief Tech/Sci/R&D Officer 69 2024-02-29
General Counsel - -
Director TitleAgeSince
Chairman 61 2022-04-30
Director/Board Member 51 2022-04-30
Director/Board Member 63 2022-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/11/26 Buy

Chairman

16,000 0.0528%
5/12/26 Free

Director

161,481 0.5039%
5/12/26 Exercice

Director

211,850 0.6611%
Change 5-day change 1-year change 3-year change Capi.($)
+5.41%+0.86%-59.23%-78.53% 33.55M
+1.91%+3.75%-16.52%+10.62% 119B
+2.01%+2.53%-6.41%+44.65% 79.44B
+1.90%+2.06%-32.83%-16.76% 43.95B
+1.13%+2.99%-0.93%+9.41% 40.83B
+3.89%+8.59%-24.55%-2.31% 30.09B
+3.17%+2.52%-30.17%-8.06% 18.65B
+3.79%+9.85%-32.27%-37.08% 17.92B
+2.18%+4.16%-39.28%-20.13% 17.1B
+1.18%+0.98%+10.72%+57.98% 16.05B
Average +2.20%+2.60%-23.15%-4.02% 38.28B
Weighted average by Cap. +0.92%+3.08%-16.54%+10.86%

Financials

2026 *2027 *
Net sales 178M 159M 148M 135M 253M 17.23B 256M 1.78B 696M 8.76B 668M 654M 28.16B 188M 168M 156M 142M 267M 18.17B 270M 1.88B 734M 9.23B 704M 689M 29.7B
Net income -5.99M -5.35M -4.99M -4.54M -8.53M -580M -8.62M -59.94M -23.45M -295M -22.5M -22.01M -949M 3.76M 3.36M 3.14M 2.85M 5.36M 365M 5.41M 37.66M 14.73M 185M 14.14M 13.83M 596M
Net Debt - -
Projected Income Statement - Annual - biote Corp.
Logo biote Corp.
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Employees
223
Date Price Change Volume
26-10-08 US$1.170 +5.41% 149,696
26-10-07 US$1.110 -2.63% 194,957
26-10-06 US$1.140 +1.79% 231,341
26-10-05 US$1.120 -2.61% 205,195
26-10-02 US$1.150 -0.86% 125,383
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - biote Corp.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.170USD
Average target price
2.612USD
Spread / Average Target
+123.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - biote Corp.
  1. Stock Market
  2. Stocks
  3. BTMD Stock